Document:

Filed by Bowne Pure Compliance

Exhibit 10.3

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR UNLESS
SUCH TRANSACTION IS IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

NORTHWEST BIOTHERAPEUTICS, INC.

WARRANT

			
	 	 	 
	No. BW-2008-_____ 

	 	October 1, 2008

This Certifies That, for value received, SDS Capital Group SPC, Ltd., with its principal
office in Old Greenwich, CT 06870, and/or its assigns (collectively, the “Holder”), is entitled to
subscribe for and purchase from Northwest Biotherapeutics, Inc., a Delaware corporation, with its
principal office in Bethesda, Maryland (the “Company”), such number of Exercise Shares as provided
herein at the Exercise Price as provided herein. This Warrant is being issued pursuant to the terms
of that certain Loan Agreement and Promissory Note, of even date herewith, by and among the Company
and Holder (the “Note”).

1. Definitions. Capitalized terms used but not defined herein shall have the meanings set
forth in the Note, as applicable. As used herein, the following terms shall have the following
respective meanings:

(a) “Common Stock” shall mean the common stock of the Company, par value $0.001 per share.

(b) “Exercise Period” shall mean the period commencing on the date of issuance of this Warrant
and ending five (5) years after the date of issuance of this Warrant.

(c) “Exercise Price” of this Warrant shall be equal to $0.53 per share, subject to adjustment
as provided herein.

(d) “Exercise Share” shall mean each of the 697,775 shares of Common Stock for which this
Warrant is exercisable.

2. Exercise of Warrant. This Warrant will be fully vested and exercisable upon issuance. The
rights represented by this Warrant may be exercised in whole or in part at any time or times during
the Exercise Period, by delivery of the following to the Company at its address set forth above (or
at such other address as it may designate by notice in writing to the Holder):

(a) An executed Notice of Exercise in the form attached hereto;

(b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of
indebtedness; and

(c) This Warrant.

 

 

 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for
the Exercise Shares so purchased, registered in the name of the Holder or Holder’s designee(s),
shall be issued and delivered to the Holder within a reasonable time after the rights represented
by this Warrant shall have been so exercised. In the event that this Warrant is being exercised for
less than all of the then-current number of Exercise Shares purchasable hereunder, the Company
shall, concurrently with the issuance by the Company of the number of Exercise Shares for which
this Warrant is then being exercised, issue a new Warrant exercisable for the remaining number of
Exercise Shares purchasable hereunder.

The person in whose name any certificate or certificates for Exercise Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on
the date on which this Warrant was surrendered and payment of the Exercise Price was made,
irrespective of the date of delivery of such certificate or certificates, except that, if the date
of such surrender and payment is a date when the stock transfer books of the Company are closed,
such person shall be deemed to have become the holder of such shares at the close of business on
the next succeeding date on which the stock transfer books are open.

2.1 Net (Cashless) Exercise. Notwithstanding any provisions herein to the contrary, if the
fair market value of one Exercise Share is greater than the Exercise Price (at the date of
calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder
may elect to receive shares equal to the value (as determined below) of this Warrant (or the
portion thereof being canceled) by surrender of this Warrant at the principal office of the Company
together with the properly endorsed Notice of Exercise in which event the Company shall issue to
the Holder a number of Exercise Shares computed using the following formula:

	 	 	 
	 

	 	X = Y (A-B)
           A
	 
	 	 
	Where X =

	 	the number of Exercise Shares to be issued to the Holder
	 
	 	 
	Y =

	 	the number of Exercise Shares purchasable under the Warrant or, if only a
portion of the Warrant is being exercised, that portion of the Warrant being
canceled (at the date of such calculation)
	 
	 	 
	A =

	 	the fair market value of one Exercise Share (at the date of such calculation)
	 
	 	 
	B =

	 	Exercise Price (as adjusted to the date of such calculation)

For purposes of the above calculation, the fair market value of one Exercise Share shall be
determined by the Company’s Board of Directors in good faith; provided, however, that in the event
that this Warrant is exercised pursuant to this Section 2.1 in connection with a public offering
of Common Stock, the fair market value per share shall be the product of (i) the per share offering
price to the public in such public offering, and (ii) the number of shares of Common Stock into
which each Exercise Share is convertible at the time of such exercise.

 

 2.

 

2.2 Securities for Which Warrant is Exercisable. This Warrant shall be exercisable, in
whole or in part, and from time to time, for Common Stock of the Company.

3. Covenants of the Company.

3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise
Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes,
liens and charges with respect to the issuance thereof. The Company further covenants and agrees
that the Company will at all times during the Exercise Period, have authorized and reserved, free
from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise
of the rights represented by this Warrant. If at any time during the Exercise Period the number of
authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this
Warrant, then, in addition to such other remedies as may be available to Holder, including, without
limitation, pursuant to the Note, the Company will take such corporate action as shall be necessary
to increase its authorized but unissued shares of Common Stock to such number of shares as shall be
sufficient for such purposes.

3.2 Notices of Record Date. In the event of any taking by the Company of a record of the
holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at
least ten (10) days prior to the date specified herein, a notice specifying the date on which any
such record is to be taken for the purpose of such dividend or distribution.

3.3 No Impairment. The Company shall not, by amendment of its Charter or through a
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities, or any other voluntary action, omission or agreement, avoid or seek to avoid the
observance or performance of any of the terms to be observed or performed by the Company under
and/or in connection with this Warrant, but shall at all times in good faith use best efforts to
assist in carrying out of all the provisions of and/or relating to this Warrant and in taking all
such action as may be necessary or appropriate to protect
Holder’s rights, preferences and privileges under and/or in connection with this Warrant
against impairment. The Holder’s rights, preferences and privileges granted under and/or in
connection with this Warrant may not be amended, modified or waived without the Holder’s prior
written consent, and the documentation providing for such rights, preferences and privileges will
specifically provide as such.

3.4 Registration Rights. The Company will use commercially reasonable best efforts to
obtain treatment of the Exercise Shares as “registrable securities” (or terms of similar impact)
under any agreement executed by the Company for financing of the Company, for purposes of providing
registration rights under the Securities Act of 1933, as amended (the “Act”) to holders of the
Warrant and/or Common Stock issued pursuant to exercise of the Warrant.

 

 3.

 

4.
Representations of Holder.

4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that
it is acquiring the Warrant and the Exercise Shares solely for its account for
investment and not with a view to or for sale or distribution of said Warrant or Exercise
Shares, or any part thereof, except in compliance with applicable federal and state securities
laws. The Holder also represents and warrants that the all legal and beneficial interests in the
Warrant and the Exercise Shares which the Holder is acquiring are being acquired for, and will be
held for, its account only.

4.2 Securities Are Not Registered.

(a) The Holder understands that the Warrant and the Exercise Shares have not been
registered under the Act on the basis that no distribution or public offering of the stock of the
Company is to be effected by the Holder. The Holder realizes that the basis for the exemption may
not be present if, notwithstanding its representations, the Holder has a present intention of
acquiring the securities for a fixed or determinable period in the future, selling (in connection
with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder represents and warrants that it has no such present intention.

(b) The Holder recognizes that the Warrant and the Exercise Shares must be held
indefinitely unless they are subsequently registered under the Act or an exemption from such
registration is available.

(c) The Holder is aware that neither the Warrant nor the Exercise Shares may be sold
pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among
other things, the availability of certain current public information about the Company, the resale
following the required holding period under Rule 144 and the
number of shares being sold during any three month period not exceeding specified limitations.

4.3 Disposition of Warrant and Exercise Shares.

The Holder understands and agrees that all certificates evidencing the shares to be issued to
the Holder may bear the following legend:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR UNLESS SUCH TRANSACTION IS
IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

4.4 Accredited Investor Status. The Holder is an “accredited investor” as defined in
Regulation D promulgated under the Act.

5.
Adjustment of Exercise Price and Exercise Shares.

5.1 Changes in Securities. In the event of changes in the Common Stock by reason of stock
dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares,
separations, reorganizations, liquidations, or the like, the number of Exercise Shares
available under the Warrant in the aggregate and the Exercise Price shall be correspondingly
adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the
same shares as the Holder would have owned had the Warrant been exercised prior to the event and
had the Holder continued to hold such shares until after the event requiring adjustment. For
purposes of this Section 5, the “Aggregate Exercise Price” shall mean the aggregate Exercise Price
payable in connection with the exercise in full of this Warrant. The form of this Warrant need not
be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.

 

 4.

 

5.2 Certificate of Adjustments. Upon each adjustment of the Exercise Price and/or
Exercise Shares, the Company shall promptly notify the Holder in writing and furnish the Holder
with a certificate of its Chief Executive Officer or Chief Financial Officer setting forth such
adjustment and the facts upon which such adjustment is based.

6. Fractional Shares. No fractional shares shall be issued upon the exercise of this
Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including
fractions) to be issued upon exercise of this Warrant shall be aggregated for purposes of
determining whether the exercise would result in the issuance of any fractional share. If, after
aggregation, the exercise would result in the issuance of a
fractional share, the Company shall, in lieu of issuance of any fractional share, pay the
Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from
multiplying the then current fair market value of one Exercise Share by such fraction.

7. Transfer of Warrant. Subject to applicable laws, this Warrant and all rights hereunder
are transferable, in whole or in part, at any time or times by the Holder, upon delivery of this
Warrant and the form of assignment attached hereto to any transferee designated by Holder. The
transferee shall sign a customary investment letter in form and substance reasonably satisfactory
to the Company.

8. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost,
stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as
it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen,
mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of
the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at
any time enforceable by anyone.

9. Amendment. Any term of this Warrant may be amended or waived only with the written
consent of the Company and the Holder.

10. Notices, etc. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given upon actual delivery to the recipient. All communications shall
be sent to the Company and to the Holder at the addresses listed on the signature page hereof or at
such other address as the Company or Holder may designate by written notice to the other parties
hereto.

 

 5.

 

11. Governing Law. This Warrant and all rights, obligations and liabilities
hereunder shall be governed by and construed under the laws of the State of New York
as applied to agreements among New York residents, made and to be performed entirely
within the State of New York without giving effect to conflicts of laws principles.

[Signature Page Follows]

 

 6.

 

In Witness Whereof, the Company has caused this Warrant to be executed by its duly authorized
officer as of the date first written above.

	 	 	 	 	 
	 	Northwest Biotherapeutics, Inc.

 	 
	 	By:  	/s/ Alton Boynton
 	 
	 	 	Name: 	Alton Boynton 	 
	 	 	Title: 	President

	 
	 
	 	 	Address: 	7600 Wisconsin Ave

Suite 750

Bethesda, MD      20814 	 
	 

ACKNOWLEDGED AND AGREED:

SDS Capital GROUP SPC, LTD.

	 	 	 	 	 
	By:

	 	/s/ Steve Derby
 

	 	 
	 

	 	Name: Steve Derby	 	 
	 

	 	Title:   Chief Investment Officer	 	 
	 
	 	 	 	 
	 	 	Address: 53 Forest Avenue, Suite 201 

Old Greenwich, CT 06870
	 	 

[Signature Page to Warrant No. BW-2007-___]

  

 

NOTICE OF EXERCISE

TO: Northwest Biotherapeutics, Inc.

(1) o The undersigned hereby elects to purchase
 _____ 
shares of Common Stock (the
“Exercise Shares”) of Northwest Biotherapeutics, Inc. (the “Company”) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.

o The undersigned hereby elects to purchase
 _____ 
shares of Common Stock (the
“Exercise Shares”) of Northwest Biotherapeutics, Inc. (the “Company”) pursuant to the terms of the
net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment
of all applicable transfer taxes, if any.

(2) Please issue a certificate or certificates representing said Exercise Shares in the name
of the undersigned or in such other name as is specified below:

	 	 	 	 	 
	 

	 	 

(Name)
	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 

	 	 

(Address)
	 	 

(3) The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for
the account of the undersigned for investment and not with a view to, or for resale in connection
with, the distribution thereof and that the undersigned has no present intention of distributing or
reselling such shares, except in accordance with applicable
federal and state securities laws; (ii) the undersigned is aware of the Company’s business affairs
and financial condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned
is experienced in making investments of this type and has such knowledge and background in
financial and business matters that the undersigned is capable of evaluating the merits and risks
of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands
that Exercise Shares issuable upon exercise of this Warrant have not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from
the registration provisions of the Securities Act, which exemption depends upon, among other
things, the bona fide nature of the investment intent as expressed herein, and, because such
securities have not been registered under the Securities Act, they must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is
available; (v) the undersigned is aware that the aforesaid Exercise Shares may not be sold pursuant
to Rule 144 adopted under the Securities Act unless certain conditions are met and until the
undersigned has held the shares for the number of years prescribed by Rule 144, that among the
conditions for use of the Rule is the availability of current information to the public about the
Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the
aforesaid shares of Exercise Shares unless and until there is then in effect a registration
statement under the Securities Act covering such proposed disposition or unless such transaction is
in compliance with applicable federal and state securities laws.

	 	 	 
	 

	 	 
	(Date)

	 	(Signature)
	 
	 	 
	 

	 	 
	 

	 	(Print name)

 

 1.

 

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and

supply required information. Do not use this form to

purchase shares.)

For
Value Received, the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

	 	 	 
	Name:
	 	 
	 

	 	 
	 

	 	(Please Print)
	 
	 	 
	Address:
	 	 
	 

	 	 
	 

	 	(Please Print)

Dated:                     , 20__

	 	 	 	 	 
	Holder’s
	 	 	 	 
	Signature:
	 	 	 	 
	 

	 	 

	 	 
	Holder’s
	 	 	 	 
	Address:
	 	 	 	 
	 

	 	 

	 	 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face
of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of
authority to assign the foregoing Warrant.

 

 2.Filed by Bowne Pure Compliance

Exhibit 10.4

NORTHWEST BIOTHERAPEUTICS, INC.

LOAN AGREEMENT and

PROMISSORY NOTE

			
	 	 	 
	US $1 million
	 	October 21, 2008

SECTION 1. GENERAL.

SDS Capital Group SPC, Ltd, a company, (“SDS” or the “Holder”) hereby grants to Northwest
Biotherapeutics, Inc., a Delaware company (the “Maker” or the “Company”) an unsecured bridge term
loan facility of One Million Dollars (US$1.0 million) (the “Principal Amount”) subject to the terms
of this Loan Agreement and Promissory Note (this “Note”). The funding at closing of this Note will
be US$1.0 million, and the repayment on the Maturity Date will be US$1.06 million (the “Repayment
Amount”). In addition, upon execution of this Note, Maker will issue to Holder a Warrant
exercisable for common stock of Maker as provided in Section 10 hereof. Holder shall advance the
Principal Amount to the Company promptly following execution of this Note at the account notified
to Holder by the Company.

Upon receipt of the Principal Amount and for value received, the Company hereby promises to issue
the Warrant, and promises to pay the Repayment Amount to the order of the Holder or its assigns, in
accordance with this Note, on April 21, 2009, or such earlier date as may be applicable under
Sections 3 and 4 hereof (the “Maturity Date”).

SECTION 2. PRE-PAYMENT.

This Note may be pre-paid prior to the Maturity Date at any time, at the election of the Maker in
its discretion, provided however that any such pre-payment shall have no effect upon the Warrant.

SECTION 3. DEFAULT PAYMENT.

Upon the occurrence of an Event of Default (as defined in Section 4 hereof) after notice as
provided in Section 17.1 hereof (“Event of Default”), default payments shall become due and payable
on any unpaid Repayment Amount that remains outstanding after the applicable Maturity Date (the
“Default Principal”). The default payments shall be assessed on a monthly basis at the beginning of
each month or partial month in which any Default Principal remains outstanding. Such default
payments shall be a fixed amount relating to such month or partial month, and shall not be pro
rated if the Default Principal is repaid by the Maker during such month. The amount of such
default payments shall be equal to the lowest of (i) 0.25% percent of the Default Principal per
month or partial month that such Default Principal remains outstanding, representing an annualized
rate of Default Payments of three percent (3%) per annum, or (ii) the maximum rate permitted under
applicable rules and regulations of the United States Small Business Administration (“SBA”), or
(iii) the maximum rate allowed by law (the “Default Payments”). Such Default Payments shall
commence upon the occurrence of an Event of Default and continue until such Event of Default is
fully cured or waived.

 

 

 

SECTION 4. DEFAULTS.

4.1 Definitions. Each occurrence of any of the following events shall
constitute an “Event of Default”:

(a) if a default occurs in the issuance of the Warrant or in the payment of any Repayment
Amount, or other amounts due under this Note, whether at the due date thereof or upon acceleration
thereof, and such default remains uncured for ten (10) business days after written notice thereof
from Holder;

(b) if any representation or warranty of Maker made herein shall have been false or misleading
in any material respect, or shall have contained any material omission, as of the date hereof;

(c) if a material default occurs in the due observance or performance on the part of Maker of
any covenant or agreement to be observed or performed pursuant to the terms of this Note and such
default remains uncured for ten (10) business days after written notice thereof from Holder;

(d) if Maker shall (i) discontinue its business, (ii) apply for or consent to the appointment
of a receiver, trustee, custodian or liquidator of Maker or any of its property, (iii) make a
general assignment for the benefit of creditors, or (iv) file a voluntary petition in bankruptcy,
or a petition or an answer seeking reorganization or an arrangement with creditors, or take
advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or
liquidation laws or statutes, or file an answer admitting the material allegations of a petition
filed against it in any proceeding under any such law;

(e) if there shall be filed against Maker an involuntary petition seeking reorganization of
Maker or the appointment of a receiver, trustee, custodian or liquidator of Maker or a substantial
part of its assets, or an involuntary petition under any bankruptcy, reorganization or insolvency
law of any jurisdiction, whether now or hereafter in effect (any of the foregoing petitions being
hereinafter referred to as an “Involuntary Petition”) and such Involuntary Petition shall not have
been dismissed within ninety (90) days after it was filed;

4.2 Remedies on Default.

(a) Upon each and every such Event of Default and at any time thereafter during the
continuance of such Event of Default: (i) any and all indebtedness and related amounts (including,
without limitation, Default Payments) due from Maker to Holder under this Note or otherwise shall
immediately become due and payable; and (ii) Holder may exercise all the rights of a creditor under
applicable law.

(b) In case any one or more Events of Default shall occur and be continuing, and acceleration
of this Note or any other indebtedness or obligation of Maker to Holder shall have occurred, Holder
may, inter alia, proceed to protect and enforce its rights by an action at law,
suit in equity and/or other appropriate proceeding, whether for the specific performance of any
agreement contained in this Note, or for an injunction against a violation of any of the terms
hereof or thereof or in furtherance of the exercise of any power granted hereby or thereby or by
law. No right conferred upon Holder by this Note shall be exclusive of any other right referred to
herein or therein or now or hereafter available at law, in equity, by statute or otherwise.

 

 

 

SECTION 5. DEFENSES.

The obligations of Maker under this Note shall not be subject to reduction, limitation,
impairment, termination, defense, set-off, counterclaim or recoupment for any reason.

SECTION 6. EXTENSION OF MATURITY.

Should the Repayment Amount or any other amounts due under this Note become due and payable on
other than a business day, the due date thereof shall be extended to the next succeeding business
day. For the purposes of the preceding sentence, a business day shall be any day that is not a
Saturday or Sunday, or a legal holiday in the State of New York in the United States.

SECTION 7. ATTORNEYS’ FEES AND COLLECTION FEES.

In the event that all or part of the indebtedness evidenced by this Note is collected at law
or in equity, or in bankruptcy, receivership or other court proceedings, arbitration or mediation,
or any settlement of any of the foregoing, Maker agrees to pay, in addition to the Repayment Amount
and any other amounts due and payable hereunder, all costs of collection incurred by Holder in
collecting or enforcing this Note, including, without limitation, reasonable attorneys’ fees and
expenses.

SECTION 8. WAIVERS, DISPUTES, JURISDICTION.

8.1 Waivers by Maker. Maker hereby waives presentment, demand for payment,
notice of dishonor, notice of protest and all other notices or demands in connection with the
delivery, acceptance, performance or default of this Note.

8.2 Actions of Holder not a Waiver. No delay by Holder in exercising any
power or right hereunder shall operate as a waiver of any power or right, nor shall any single or
partial exercise of any power or right preclude other or further exercise thereof, or the exercise
of any other power or right hereunder or otherwise; and no waiver or modification of the terms
hereof shall be valid unless set forth in writing by Holder and then only to the extent set forth
therein.

8.3 Consent to Jurisdiction. Maker hereby submits to the jurisdiction of any state
or federal court sitting in the State of New York over any suit, action, or proceeding arising out
of or relating to this Note or any other agreements or instruments with respect to Holder. Maker
hereby waives, to the fullest extent permitted by law, any objection that Maker may now or
hereafter have to the laying of venue of any such suit, action, or proceeding brought in any such
court and any claim that any such suit, action, or proceeding brought in any such court has been
brought in an inconvenient forum. Final judgment in any such suit, action, or proceeding brought
in any such court shall be conclusive and binding upon Maker, and may be enforced in any court in
which Maker is subject to jurisdiction by a suit upon such judgment, provided that service of
process is effected upon Maker as provided in this Note or as otherwise permitted by applicable
law.

 

 

 

8.4 Waiver of Jury Trial. MAKER WAIVES ANY RIGHTS IT MAY HAVE TO A JURY TRIAL
OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF THIS AGREEMENT OR ANY DEALINGS BETWEEN MAKER AND
HOLDER RELATING TO THE SUBJECT MATTER OF THIS NOTE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE
ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE
SUBJECT MATTER OF THIS NOTE, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, AND ALL
OTHER COMMON LAW AND STATUTORY CLAIMS. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE
MODIFIED EITHER ORALLY OR IN WRITING, AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS,
SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENT OR AGREEMENT RELATING TO
THE LOAN.

8.5 Service of Process. Maker hereby consents to process being served in any
suit, action, or proceeding instituted in connection with this Note by delivery of a copy thereof
by certified mail, postage prepaid, return receipt requested, to Maker, and/or by delivery of a
copy thereof to a registered agent of Maker. Refusal to accept delivery, and/or avoidance of
delivery, shall be deemed to constitute delivery. Maker irrevocably agrees that service in
accordance with this Section 8.5 shall be deemed in every respect effective service of process upon
Maker in any such suit, action or proceeding, and shall, to the fullest extent permitted by law, be
taken and held to be valid personal service upon Maker. Nothing in this Section 8.5 shall affect
the right of Holder to serve process in any manner otherwise permitted by law or limit the right of
Holder otherwise to bring proceedings against Maker in the courts of any jurisdiction or
jurisdictions.

SECTION 9. COVENANTS.

9.1 Affirmative Covenants. So long as this Note shall remain outstanding:

(a) Office. Maker shall maintain its head office in the United States.

(b) Use of Proceeds. Maker shall use the proceeds from this Note for operating
expenses and other obligations of the Company incurred in pursuing the Company’s business plan and
strategy for Israel including, without limitation, product rollout in Israel, activities involving
countries outside Israel based upon the Israeli facilities and capacity, clinical trial expenses,
research and development expenses, expenses related to regulatory filings and processes with the US
Food and Drug Administration (“FDA”) and applicable regulators in various international markets,
preparations for commercial delivery of the Company’s products in various international markets,
expenses related to US Securities and Exchange Commission (“SEC”) filings and processes, expenses
related to salaries and other general and administrative
operations, expenses related to litigation, and expenses of accountants, attorneys, consultants and
other professionals.

 

 

 

(c) Regulatory Information. So long as any principal or other obligation under this
Note shall remain outstanding, Maker shall provide to Holder, within the applicable timeframe
specified by Holder, all such information and assessments as may be necessary or desirable in order
for Holder to comply with its reporting obligations to any governmental agency or authority
including, without limitation, the SBA. To the extent that any such information constitutes
material non-public information, Holder agrees to keep such information confidential in accordance
with applicable securities laws.

(d) Business Activity. So long as any principal or other obligation under
this Note shall remain outstanding, Maker shall make no change in its business activity that would
render it or any of its business activities non-compliant with SBA regulations and guidelines.

9.2 Negative Covenants. So long as any principal or other obligation under
this Note shall remain outstanding:

(a) No Liens. Maker shall not grant to any person or entity a security interest,
lien, license, or other encumbrance of any kind, direct or indirect, contingent or otherwise, in,
to or upon any assets of Maker, including, without limitation, any intellectual property of any
kind (collectively, “Liens”), except (i) Liens to secure further financing for the purpose of (x)
repaying the Principal Amount and any other amounts due pursuant to this Note and any other notes
under which the repayment of principal and other consideration is pari passu with the repayment
under this Note, or (y) funding the further operations of the Company, or (ii) Liens imposed by law
for taxes that are not yet due or are being contested in good faith by the Company.

(b) No Conflicting Agreements. Maker shall not enter into any agreement that
would materially impair, interfere or conflict with Maker’s obligations hereunder.

SECTION 10. WARRANT

In partial consideration for the loan made by Holder pursuant to this Note, Maker will issue
to Holder at Closing a warrant exercisable for the purchase of common stock of the Maker, in the
form attached hereto as Exhibit A (the “Warrant”). As provided in the Warrant, the exercise price
will be equal to the lowest closing price of Maker’s common stock on the US NASDAQ OTC Bulletin
Board market or the London AIM market on the trading day prior to the date of execution of this
Note (the “Exercise Price”). The number of shares for which the Warrant will be exercisable will
be the number of shares of Maker’s common stock which, when multiplied by the Exercise Price, have
a value equal to fifty percent (50%) of the Repayment Amount.

 

 

 

SECTION 11. MAKER’S REPRESENTATIONS AND WARRANTIES.

Except as disclosed in the Maker’s public filings with the SEC, Maker represents and warrants the
following:

11.1 Organization, Good Standing and Qualification. Maker is a corporation
duly organized, validly existing and in good standing under the laws of the State of Delaware in
the United States, and has all requisite corporate power and authority to carry on its business.
Maker is duly qualified to transact business and is in good standing in each jurisdiction in which
the failure so to qualify would have a material adverse effect on its business, properties,
operations, prospects or condition (financial or otherwise).

11.2 Authorization. The execution, delivery and performance by Maker of this
Note, and the transactions contemplated hereunder (including, without limitation, the issuance of
common stock pursuant to exercise of the Warrant), have been duly authorized by all requisite
corporate action by Maker in accordance with Delaware law. This Note is a valid and binding
obligation of Maker, enforceable against Maker in accordance with its terms, except as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general application
affecting enforcements of creditors’ rights or general principles of equity.

11.3 No Conflicts. The execution, delivery, performance, issuance, sale and
delivery of this Note and compliance with the provisions hereof by Maker will not, to the knowledge
of Maker, (a) violate any provision of any law, statute, rule or regulation applicable to Maker or
any order, judgment or decree of any court, arbitrator, administrative agency or other governmental
body applicable to Maker or any of its assets or (b) conflict with or result in any material breach
of any of the terms or conditions of any agreement or instrument to which Maker is a party, or give
rise to any right of termination, cancellation or acceleration under any such agreement or
instrument, or result in the creation of any lien or other encumbrance upon any of the material
assets of Maker.

11.4 “Small Business”.

(a) Small Business Status. Maker together with its “affiliates” (as that term is
defined in Section 121.103 of Title 13 of Code of Federal Regulations (the “Federal Regulations”))
is a “small business concern” within the meaning of the Small Business Investment Act of 1958, as
amended (the “Small Business Act” or “SBIA”), and the regulations promulgated thereunder, including
Section 121.301(c) of Title 13, Code of Federal Regulations.

(b) Information for SBA Reports. Maker has delivered and/or will deliver to Holder
certain information, set forth by and regarding the Maker and its affiliates in connection with
this Note, on SBA Forms 480, 652 and Part A and B of Form 1031. This information delivered was
true, accurate, complete and correct in all material respects, and any information yet to be
delivered will be true, accurate, complete and correct in all material respects, and in form and
substance acceptable to Holder.

(c) Eligibility. Maker is eligible for financing by Holder pursuant to Section
107.720 of Title 13 of the Federal Regulations and any other SBA regulations.

 

 

 

SECTION 12. HOLDER’S REPRESENTATIONS AND WARRANTIES

12.1 Unregistered Shares. Holder understands that the shares of common stock to be
issued to Holder pursuant to the Warrant (the “Warrant Shares”) will not be registered within any
designated timeframe thereafter under the Securities Act of 1933, as amended (the “Securities
Act”). Holder also understands that issuance of the Warrant Shares will be pursuant to an
exemption from registration contained in the Securities Act based in part upon Holder’s
representations herein.

12.2 Accredited Investor. Holder hereby represents and warrants that Holder has
substantial experience in evaluating and investing in securities, and is capable of evaluating the
merits and risks of its loan to Maker under this Note and any investmentin the Warrant Shares, and
has the capacity to protect its own interests. Holder is an “accredited investor” within the
meaning of Regulation D under the Securities Act.

12.3 Investment Purpose. Holder is acquiring the Warrant and the Warrant Shares for
its own account for investment only, and not with a view towards distribution. Holder is not aware
of publication of any advertisement in connection with the issuance of the Warrant or the Warrant
Shares.

SECTION 13. INDEMNIFICATION

13.1 Indemnification.

(a) In addition to all rights and remedies available to Holder at law or in equity, Maker
shall indemnify Holder and each subsequent holder of this Note, and their respective affiliates,
stockholders, limited partners, general partners, officers, directors, managers, employees, agents,
representatives, successors and assigns (collectively, the “Indemnified Persons”) and pay on behalf
of or reimburse such party for any losses, damages, or expenses, including, without limitation,
reasonable attorneys’ fees and all amounts paid in investigation, defense or settlement of any of
the foregoing which any Indemnified Person may suffer, sustain or become subject to as a result of
or in connection with any material misrepresentation in, or material omission from, any of the
representations and warranties, or any material breach of any covenant or agreement on the part of
Maker under this Note, provided, however, that notwithstanding the foregoing or any other agreement
or provision to the contrary, in no event shall Maker be liable for indirect or consequential
losses or damages of any kind, and in no event shall Maker be liable for any losses or damages
resulting from the gross negligence or willful misconduct of Holder or a subsequent holder of this
Note.

(b) Within five (5) business days after receipt of notice of commencement of any action or the
assertion of any claim by a third party, Holder shall give Maker written notice thereof together
with a copy of such claim, process or other legal pleading of such claim. Maker
shall have the right to assist in the defense thereof by representation of its own choosing, at its
own expense.

 

 

 

13.2 Survival. All indemnification rights hereunder shall survive the
execution and delivery of this Note and the consummation of the transactions contemplated
hereunder, for a period of two (2) years, regardless of any investigation, inquiry or examination
made for or on behalf of, or any knowledge of Holder and/or any of the Indemnified Persons, or the
acceptance by Holder of any certificate or opinion.

SECTION 14. SUBSEQUENT FINANCING.

Subject to Section 2 above, until the Repayment Amount has been paid in full, if and when Maker
completes an offering (the “Subsequent Financing”) of (i) equity or equity-linked securities, or
(ii) debt that is convertible into equity or in which there is an equity component (the “Additional
Securities”), Maker shall offer participation in such Subsequent Financing to Holder in accordance
with the following provisions:

A. At least three (3) trading days prior to, or within three (3) trading days
after, the closing of the offering of Additional Securities, Maker shall deliver to Holder a
written notice of such offering (the “Subsequent Financing Notice”), which Subsequent Financing
Notice shall ask the Holder if it wants to review the details of such financing (the “Subsequent
Financing Description”). Upon the request of Holder for a Subsequent Financing Description, Maker
shall promptly, but no later than two (2) trading days after such request, deliver a Financing
Description to Holder. The Financing Description shall describe in reasonable detail the proposed
terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder, the
Person(s) with whom such Subsequent Financing is proposed to be effected (provided that the name of
such Person(s) is available, and provided further that Holder agrees not to make or receive with
contact such Person(s) except with Maker’s prior written consent in its sole discretion), and
attached to which shall be a term sheet or similar document relating thereto.

B. By written notification received by Maker by 6:30 p.m. (New York City time)
on the second (2nd) trading day after its receipt of the Subsequent Financing Notice,
Holder may elect to purchase or obtain, at the price and on the terms specified in the Subsequent
Financing Description, such number of Additional Securities as is equal to the then outstanding
portion of the principal amount pursuant to this Note on the terms and conditions set forth in the
Subsequent Financing Description, subject to mutually acceptable documentation; provided, that
Holder shall pay for the Additional Securities by surrendering, and Maker shall receive payment by
accepting such surrender, of the then outstanding principal balance of this Note. Upon the
surrender of such principal amount as payment for Additional Securities, Maker (itself, or through
its transfer agent) shall, no later than the third business day following such surrender, issue and
deliver (i.e., deposit with a nationally recognized overnight courier service postage prepaid) to
Holder or its nominee certificates or other instruments evidencing the Additional Securities
purchased by Holder.

 

 

 

SECTION 15. MISCELLANEOUS.

15.1 Notices. All notices, demands and requests of any kind to be delivered
to any party in connection with this Note shall be in writing and shall be deemed to be effective
upon delivery if (i) personally delivered, (ii) sent by confirmed facsimile with a copy sent by
nationally or internationally recognized overnight courier, (iii) sent by nationally or
internationally recognized overnight courier, or (iv) sent by registered or certified mail, return
receipt requested and postage prepaid, addressed as follows:

	 	 	 
	if to Maker:
	 	Northwest Biotherapeutics, Inc.
	 
	 	7600 Wisconsin Avenue
	 
	 	Suite 750
	 
	 	Bethesda, MD  20814
	 
	 	Tel:   +1-240-497-4060
	 
	 	Fax:   +1-240-497-4065
	 
	 	Attention:   Alton Boynton
	 
	 	aboynton@nwbio.com
	 
	 	 
	with a copy to:
	 	David Engvall, Esq.
	 
	 	Covington & Burling
	 
	 	1201 Pennsylvania Avenue, N.W.
	 
	 	Washington, DC  20004-2401
	 
	 	Tel:  +1-202-662-5307
	 
	 	Fax: +1- 202-778-5307
	 
	 	dengvall@cov.com
	 
	 	 
	if to Holder:
	 	 
	 
	 	 
	with a copy to:
	 	 

or to such other address as the party to whom notice is to be given may have furnished to the other
parties hereto in writing in accordance with the provisions of this Section.

15.2 Parties In Interest; Assignment. This Note shall bind and inure to the
benefit of Holder, Maker and their respective successors and permitted assigns. Maker shall not
transfer or assign this Note without the prior written consent of Holder. Holder may transfer and
assign this note without the prior consent of Maker.

 

 

 

15.3 Entire Agreement. This Note contains the entire understanding of the
parties with respect to the subject matter hereof and supersedes all prior agreements and
understandings among the parties with respect thereto.

15.4 Severability. If one or more provisions of this Note are held to be
unenforceable under applicable law, then (i) such provision shall be excluded from this Note, (ii)
the balance of the Note shall be interpreted as if such provision were so excluded, (iii) the
balance of the Note shall be enforceable in accordance with its terms, and (iv) the parties shall
negotiate in good faith to amend or add to the provisions of this Note to effectuate as nearly as
reasonably practicable, and as nearly as permitted under applicable law, the original intent of the
parties with respect to the provision excluded.

15.5 Amendments. No provision of this Note may be amended or waived without
the express written consent of both Maker and Holder, provided, however, that Holder may waive any
provision hereof that inures to the benefit of Holder without the prior written consent of Maker.

15.6 Headings. The section and paragraph headings contained in this Note are
for reference purposes only and shall not affect in any way the meaning or interpretation of this
Note.

15.7 Governing Law. This Note shall be governed by and construed in
accordance with the laws of the State of New York, other than any rules relating to choice of law.

15.8 Nature of Obligation. This Note is being made for business and
investment purposes, and not for household or other purposes.

15.9 No Third Party Rights. A person who is not a party to this Note shall
not have any rights under or in connection with it by virtue of the Contracts (Rights of Third
Parties) Act 1999. The rights of the parties to terminate, rescind or agree any variation, waiver
or settlement under this Note is not subject to the consent of any person that is not a party to
this Note.

15.10 Counterparts. This Note may be executed and delivered in any number of
counterparts, each of which is an original and which, together, have the same effect as if each
party had signed the same document.

15.11 Replacment of Note. Upon receipt by Maker of reasonable evidence of the
loss, theft, destruction, or mutilation of this Note, Maker will deliver a new Note containing the
same terms and conditions in lieu of this Note. Any Note delivered in accordance with the
provisions of this Section 14 shall be dated as of the date of this Note.

 

 

 

IN WITNESS WHEREOF, Maker has caused this Note to be duly executed by its duly authorized
person(s) as of the date first written above.

	 	 	 	 	 	 	 	 	 	 	 
	NORTHWEST BIOTHERAPEUTICS, INC.	 	 	 	SDS CAPITAL	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Alton Boynton
	 	 	 	By:
	 	/s/  Steve Derby	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 

	 	Name: Alton Boynton
	 	 	 	 	 	Name: Steve Derby	 	 
	 

	 	Title: President
	 	 	 	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]